Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus JENLOGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus JENLOGA.
GENCEPT 10/11-21 vs JENLOGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
350 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Category C
Category C
Oral Contraceptive
Oral Contraceptive